CXT vs DBD: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

CXT is the larger of the two ($3.31B market cap): the incumbent the market prices for continued execution (12.29x forward earnings, beta 0.96). DBD is the smaller challenger ($1.90B), cheaper on forward earnings (9.21x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

CXT vs DBD: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCXTDBDWhat it tells you
Market cap$3.31B$1.90BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E12.299.21Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E26.1226.79Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.961.24Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range78% of range9% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.562.03How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: DBD is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how CXT and DBD affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CXT and DBD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CXT and DBD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Crane NXT (CXT) do?

Crane NXT, Co. makes the physical things that prove something is real and that money is money. Its Security and Authentication Technologies segment contains Crane Currency, a roughly 225-year-old business that supplies banknote paper and micro-optic security features to the US Bureau of Engraving and Printing and to central banks abroad, plus Crane Authentication, the brand-protection and government-credential unit assembled from OpSec Security and the De La Rue Authentication business bought in May 2025 for ~300 million pounds. The Detection and Traceability Technologies segment holds Crane Payment Innovations, whose bill validators, coin mechanisms and cash-recycling hardware sit inside vending machines, slot machines, self-checkout lanes and bank branches, and now Antares Vision, the Italian inspection and track-and-trace supplier acquired on April 1, 2026 and delisted from Euronext Milan. The company became a standalone issuer on April 3, 2023, when Crane Holdings separated its aerospace, industrial and process-flow operations into Crane Company (NYSE: CR) and kept the payment and security businesses under the Crane NXT name.

Full CXT guide

What does Diebold Nixdorf (DBD) do?

Diebold Nixdorf makes the machines that move cash and check out shoppers: ATMs, cash recyclers, self-checkout systems, point-of-sale terminals, and kiosks, sold through two segments (Banking and Retail) alongside the Vynamic software suite and a large installed-base services business. It is the global leader in self-checkout shipments outside China and serves a majority of the world's largest banks and retailers, so its revenue is tied to bank branch modernization, cash-recycling adoption, and retail automation cycles rather than any single fast-growing end market.

Full DBD guide

CXT vs DBD: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • CXT drivers: Currency and authentication backlog at a record; The bought pivot into authentication and traceability.
  • DBD drivers: Services mix and recurring revenue; DN Series recyclers and margin uplift.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The clearest risk is that headline growth is purchased and organic growth is barely positive, so a slower integration or a missed synergy target shows up immediately in the numbers with no underlying momentum to cushion it. For DBD, the core hardware markets (ATMs, POS, self-checkout) are mature and grow at low single digits, so structural declines in cash usage and bank branch counts are a persistent headwind.

CXT or DBD: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CXT if you believe its drivers more; DBD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CXT and DBD guides.

CXT vs DBD: the full fundamentals

CXT. Q2 2026 adjusted EPS of ~$1.10 beat consensus near ~$1.04, the fourth straight beat, and management lifted the full-year adjusted EPS range to ~$4.22 to ~$4.42 while leaving sales growth at ~15% to ~17%. Total backlog reached ~$755 million at mid-year. The stock has climbed back to about $54.87 as of October 16, 2026, still about 20% below its ~$68.54 52-week high, and the low forward multiple mainly reflects the market pricing acquisition-driven earnings and ~2.7x leverage more conservatively than organic earnings. Third-quarter consensus is EPS near $1.21 on revenue near $495 million, with results due November 4.

DBD. DBD trades around a $2.3 billion market cap with the stock near $67, still well above its August 2023 relisting price of about $20.57 but down from a 52-week high near $92. At roughly 9.6 times forward earnings and under 7 times EV to EBITDA, the multiple has compressed from the high-20s P/E the stock carried in mid-2026, so the market is now pricing in less margin expansion. Revenue growth remains modest (low single digits), and the October 28 report is the next check on free cash flow and the second-half ramp.

Headline figures (approximate, October 2026): CXT shows revenue (ttm) ~$1.80B, q2 2026 sales ~$493M (+22% YoY, ~+2.8% organic), q2 2026 adjusted eps ~$1.10 vs ~$1.04 consensus, net income (ttm) ~$140M (~7.8% profit margin); DBD shows revenue (ttm) ~$3.87B, q2 2026 revenue ~$931M (+2% YoY); adjusted EPS $1.10 vs $1.10 expected, net income (ttm) ~$111M; ~8% operating margin, 2026 adj. ebitda guidance ~$510M to $535M.

The bottom line: CXT vs DBD

CXT and DBD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CXT and DBD exposure against your real portfolio. It is not an investment adviser.

Wondering how CXT or DBD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Crane NXT

Ask Walnut's AI anything about CXT and see how it fits what you own.

FAQ

What is the difference between CXT and DBD?

+

Crane NXT, Co. Diebold Nixdorf makes the machines that move cash and check out shoppers: ATMs, cash recyclers, self-checkout systems, point-of-sale terminals, and kiosks, sold through two segments (Banking and Retail) alongside the Vynamic software suite and a large installed-base services business. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CXT or DBD the better stock?

+

Neither is universally better. CXT is the larger incumbent; DBD is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CXT or DBD?

+

On forward P/E (as of November 2026), CXT trades at 12.29x and DBD at 9.21x, so DBD is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CXT and DBD?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CXT vs DBD?

+

CXT: The clearest risk is that headline growth is purchased and organic growth is barely positive, so a slower integration or a missed synergy target shows up immediately in the numbers with no underlying momentum to cushion it. Currency orders are lumpy, sovereign and budget-dependent, and a single delayed central-bank redesign or a change in US Bureau of Engraving and Printing timing can move a quarter. The payment-acceptance business faces a genuine secular question as cash usage declines in developed markets, and its retail and vending customers are cyclical hardware buyers. Net leverage near ~2.7x after three acquisitions narrows the room for a fourth or for a downturn, and the wide gap between adjusted and GAAP earnings (~$1.10 versus ~$0.61 in Q2 2026) reflects deal amortization and integration costs that will persist for years. Competition in authentication and traceability includes far larger diversified players, and the acquired businesses were sold by their previous owners for reasons the buyer now has to fix. Analysts expect third-quarter 2026 EPS of about $1.21, roughly 6% below the prior-year quarter, so the November 4 report is a test of whether acquired revenue can offset organic softness. DBD: The core hardware markets (ATMs, POS, self-checkout) are mature and grow at low single digits, so structural declines in cash usage and bank branch counts are a persistent headwind. The company competes with well-capitalized rivals like NCR Atleos, NCR Voyix, Hyosung, and Glory, which pressures pricing on commoditizing hardware. Revenue is global with meaningful exposure to Europe and emerging markets, adding currency and macro sensitivity, and lumpy hardware order timing can make any single quarter volatile. Having so recently emerged from Chapter 11, the market is still assessing whether the improved margins are durable, and the stock has already re-rated substantially off its emergence price, leaving less margin for disappointment. Execution missteps on large rollouts or a slowdown in recycler adoption could quickly compress the margin story the valuation now assumes. The stock's roughly 24% slide over the three months to mid-October 2026 shows how quickly sentiment can turn on a quarter that was only in line, and component costs, including memory, are a swing factor in hardware margins.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CXT or DBD; figures are approximate and dated (as of November 2026). Verify current data before investing.